Dr. Kunjahari Medhi

Dr. Kunjahari Medhi is a Senior Director of Medical Oncology and Hemato-Oncology at Medanta — The Medicity in Gurugram, one of India's leading tertiary-care institutions. He holds a Doctor of Medicine (DM) in Medical Oncology from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi, and completed his clinical research fellowship at Oxford University as an INDOX Fellow. His educational foundation includes an MBBS from Assam Medical College, where he earned the Gold Medal. Dr. Medhi's clinical expertise spans the full spectrum of cancer care: systemic chemotherapy for solid tumors, both adjuvant and neoadjuvant regimens, immunotherapy using checkpoint inhibitors, and biomarker-driven targeted therapy. He manages patients with solid tumors and hematolymphoid malignancies, offering evidence-based protocols tailored to individual patient biology and disease stage. His practice reflects a commitment to molecular profiling and personalized oncology, ensuring that each patient receives cutting-edge treatment aligned with international standards. Dr. Medhi welcomes international patients from the Gulf region, Africa, and South Asia, leveraging his clinical depth and fluency in both English and Hindi to ensure seamless communication. Medanta — The Medicity provides a comprehensive oncology ecosystem, including dedicated oncology wards, advanced imaging, pathology services, and a robust supportive care team. The hospital maintains NABH accreditation and houses a specialized cancer center with multidisciplinary tumor boards. His additional training in executive management (IIM Ahmedabad) and healthcare leadership (ISB Hyderabad) enables him to navigate complex treatment pathways and coordinate care for international patients. For those seeking evidence-based oncology care in India, Dr. Medhi combines clinical rigor, research exposure, and patient-centered practice.